The stock of Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) decreased by -$1.09 on Wednesday to $19.91, down -5.19 percent. The last five days have seen an average of 1,760,285 shares of common stock traded. 6 times new highs were reached in the current year, with a fall of -$16.98. The average number of shares traded over the last 20 days was 1,309,996, while the average volume over the last 50 days totaled 1,156,398.
AMLX stock dropped -10.84% since last month. On 08/16/23, the company’s shares reached a one-month low of $19.62. The stock touched a high of $41.93 on 01/30/23, after rallying from a low of $15.80 in 52 weeks. The price of AMLX stock has declined by -46.12% or -$16.98 this year, reaching a new high 6 times. Still, the stock price is down -52.52% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
AMLX stock investors should be aware that Amylyx Pharmaceuticals Inc. (AMLX) stock had its last reported insider trading activity 92 days ago on May 16. On May 16, Chief Financial Officer FRATES JAMES M sold 32,500 shares at $26.94 each. This transaction resulted in the insider making $875,451. On May 15, Yeramian Patrick D sold 11,965 shares at a price of US$29.03. After the transaction, the insider now owns 208,417 shares. Chief Medical Officer Yeramian Patrick D had earlier sold 49,579 shares on Apr 17 for $30.54 a share. The transaction was completed for $1,513,942.
Valuation Metrics
Beta for the stock is -0.87. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 13.99, the price-to-book (PB) ratio of 3.76.
Financial Health
For the three months ended June 29, Amylyx Pharmaceuticals Inc.’s quick ratio was 7.30, while its current ratio was 7.50, indicating its ability to pay off its debt. As far as profitability goes, gross margin for the trailing twelve months is 91.20% percent. Based on annual data, it had gross profit of $19.24 million and revenue of $22.23 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. AMLX’s return on assets (ROA) during the last 12 months has been -65.80%. There was a -59.30% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -77.00%.
Earnings Surprise
According to Amylyx Pharmaceuticals Inc.’s quarterly financial report for the quarter that ended June 29, it had $109.52 million in cash and short-term investments. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $98.22 million, while revenues rose by 100.0% to $71.43 million. It was predicted that Amylyx Pharmaceuticals Inc.’s quarterly earnings would be $0.31, but it ended up being $0.1. EBITDA was $18.5 million for the quarter. At the end of Amylyx Pharmaceuticals Inc.’s most recent quarter ended June 29, its liabilities totaled 67.22 million, while its total debt was $5.29 million. Equity owned by shareholders amounts to $67.38 million.
Technical Picture
Here’s a quick look at Amylyx Pharmaceuticals Inc.’s (AMLX) price momentum from a technical perspective. As of 15 August, the RSI 9-day stood at 24.19%, suggesting the stock is oversold, with a 27.60% historical volatility rate.
The stochastic %K and %D were 16.45% and 20.44% respectively, while the average true range (ATR) was 1.02. Based on the 14-day stochastic reading of 8.54%, the RSI (14) reading is 30.65%. On the 9-day MACD Oscillator, the stock is at -0.73, and the 14-day reading is at -1.29.
Analyst Ratings
In its most recent analyst report, Goldman raised its rating on Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX) to a Buy. Prior to this, analysts firm rated the stock as a Neutral. Analysts have assigned Amylyx Pharmaceuticals Inc. (AMLX) an Buy rating. AMLX is a stock that is recommended for selling by 0 brokerage firms, while 0 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 6 others recommend it as a buy.
What is AMLX’s price target for the next 12 months?
The current consensus forecast for the stock is between $45.00 and $50.00, with a median target price of $47.00. In analyzing these forecasts, the average price target given by analysts for Amylyx Pharmaceuticals Inc. (AMLX) is $47.40.
